Kayne Anderson Rudnick Investment Management
CRSP icon

Kayne Anderson Rudnick Investment Management’s CRISPR Therapeutics CRSP Stock Holding History

Kayne Anderson Rudnick Investment Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14
Closed -$734 – 970
2025
Q4 		$734 Hold
14
– – ﹤0.01% 904
2025
Q3 		$907 Hold
14
– – ﹤0.01% 892
2025
Q2 		$681 Hold
14
– – ﹤0.01% 965
2025
Q1 		$476 Hold
14
– – ﹤0.01% 909
2024
Q4 		$551 Hold
14
– – ﹤0.01% 931
2024
Q3 		$658 Hold
14
– – ﹤0.01% 918
2024
Q2 		$756 Hold
14
– – ﹤0.01% 882
2024
Q1 		$954 Buy
+14
New +$1K ﹤0.01% 848
2023
Q4 		– Sell
-14
Closed -$635 – 970
2023
Q3 		$635 Hold
14
– – ﹤0.01% 775
2023
Q2 		$786 Hold
14
– – ﹤0.01% 768
2023
Q1 		$633 Buy
+14
New +$680 ﹤0.01% 669

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management's CRSP Position: Q1 2026 in Review

Kayne Anderson Rudnick Investment Management sold out of CRISPR Therapeutics (CRSP) in Q1 2026, closing a stake of 14 shares — an estimated $734 sold.

Kayne Anderson Rudnick Investment Management first reported a position in CRSP in Q1 2023 and held it in 11 quarters. The position peaked at $954 in Q1 2024. 489 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Kayne Anderson Rudnick Investment Management reported no remaining CRISPR Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Kayne Anderson Rudnick Investment Management sold 14 CRISPR Therapeutics shares in Q1 2026, an estimated $734.
  • Kayne Anderson Rudnick Investment Management first reported a position in CRISPR Therapeutics in Q1 2023 and held it in 11 quarters.
  • Kayne Anderson Rudnick Investment Management's CRISPR Therapeutics position peaked at $954 in Q1 2024.
  • 489 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Kayne Anderson Rudnick Investment Management's 13F filing for Q1 2026, filed 14 May 2026.